Ismail Kimji, MD, FRCPC Dr
It refers to retatrutide, a tripleagonist weightloss medication that activates GLP1, GIP, and glucagon receptors. Early clinical trials show unprecedented weightloss results, often greater than currently approved GLP1 and dualagonist drugs, along with improvements in liver fat and metabolic markers. As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLEagonist medications fit among GLP1 drugs, dualagonists, peptides, and other tools for sustainable metabolic health
A two-week medication pause is not enough
BP 157 is a compound that is marketed to improve healing, recovery, reduce pain and improve function
At Pure Med Spa Chicago, trained professionals ensure a comfortable and effective treatment experience